BRCA1-IN-2 is a cell-permeable protein-protein interaction (PPI) inhibitor for BRCA1, with IC50 of 0.31 μM and Kd of 0.3 μM. BRCA1-IN-2 has antitumor activities via the disruption of BRCA1 (BRCT)2/protein interactions.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Protein-Protein Interaction Inhibitors of BRCA1 Discovered Using Small Molecule Microarrays
Zhenkun Na, et al. Methods Mol Biol. 2017;1518:139-156. PMID: 27873205.
|Related PARP Products|
Fuzuopali is a poly (ADP-ribose) polymerase inhibitor (PARP) inhibitor with IC50 of 1.46±0.72 nM for a cell‐free enzymatic assay, with superior antitumor activity.
AZD5305 is a potent and oral active, second-generation PARP (highly selective PARP1) inhibitor.
RBN-2397 is a potent and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM).
Pamiparib (BGB-290) is an orally active, potent, highly selective inhibitor of PARP1 and PARP2 with IC50 values of 0.9 nM and 0.5 nM, respectively.
BGP-15 is a novel poly(ADP-ribose) polymerase inhibitor with an IC50 and a Ki of 120 μM and 57 μM, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.